Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Dermatologic 1

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Melanoma 1Glioma 1Glioblastoma 1Diffuse Intrinsic Pontine Glioma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 57Nivolumab 50Ipilimumab 31Specimen Handling 23Magnetic Resonance Spectroscopy 19Cyclophosphamide 14Biopsy 11fludarabine 10binimetinib 10Opdualag 10trametinib 9relatlimab 9Radiosurgery 9CTLA-4 Antigen 9dabrafenib 8lifileucel 7fludarabine phosphate 7aldesleukin 7encorafenib 6Interleukin-2 6cemiplimab 5atezolizumab 5Paclitaxel 5Blood Specimen Collection 5X-Rays 4Taxes 4Pemetrexed 4Gemcitabine 4Cisplatin 4Carboplatin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × Vaccines × 90 days × Clear all
NCT05264974 2026-05-27

Novel RNA-lipid Particle (RNA-LP) Vaccine for Anti-PD-1 Antibody Therapy Sensitization

University of Florida

Phase 1 Suspended
18 enrolled
DermatologicSarcoma

Melanoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡